Asking Your Doctor About Foundayo (Orforglipron): What to Know Before the Conversation

What Is Foundayo?

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist manufactured by Eli Lilly. The FDA approved it on April 1, 2026, for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It was approved under the Commissioner's National Priority Voucher program — the fastest approval of a new molecular entity since 2002.

Unlike oral semaglutide (Rybelsus), which must be taken on an empty stomach with limited water, Foundayo can be taken at any time of day with no food or water restrictions. That flexibility is a significant practical advantage for many patients.

What the Clinical Trials Showed

Foundayo's approval was supported by two Phase 3 trials in the ATTAIN program. In ATTAIN-1, which enrolled over 3,100 adults without diabetes, participants achieved dose-dependent weight loss ranging from 7.5% to 12.4% at 72 weeks, compared to 2.1% for placebo. The trial also showed improvements in waist circumference, blood pressure, and lipid levels.

In ATTAIN-2, which studied over 1,600 adults with type 2 diabetes, weight reductions ranged from 5.1% to 9.6% compared to 2.5% for placebo, with significant improvements in HbA1c and other cardiometabolic markers.

To put those numbers in context: injectable semaglutide (Wegovy) at its maximum dose produces roughly 15% weight loss, and tirzepatide (Zepbound) produces roughly 20%. Foundayo's 12.4% at the highest dose is lower than the top injectables but is the highest ever achieved by an oral GLP-1 medication.

Who Is a Good Candidate?

Foundayo may be worth discussing with your doctor if you meet the BMI criteria and have been avoiding GLP-1 treatment because of needle aversion, if you've tried oral semaglutide but struggled with the fasting requirements, or if you want the convenience of a daily pill you can take without restrictions.

It's also relevant for patients currently on injectable GLP-1s who want to transition to an oral format. A separate Phase 3 trial showed that patients who switched from injectable incretins to Foundayo were able to maintain their weight loss — a first-of-its-kind finding.

Side Effects Your Doctor Should Discuss

Gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — were the most common adverse events in both ATTAIN trials. These are consistent with the entire GLP-1 class. Discontinuation rates were higher with Foundayo than placebo, primarily driven by GI symptoms during the titration phase.

Your doctor should explain the dose titration schedule (starting low and increasing gradually) and offer management strategies for GI side effects, including dietary modifications like eating smaller meals and staying hydrated.

Availability and Cost

Foundayo became available through Lilly's direct-to-patient platform (LillyDirect) with shipping beginning April 6, 2026, followed by broader availability through retail pharmacies and telehealth providers. Eli Lilly has indicated that eligible Medicare Part D enrollees may pay as little as $50 per month beginning July 1, 2026.

For patients paying out of pocket, pricing details are still emerging as pharmacy networks finalize their formulary placement. Ask your doctor or pharmacist about savings programs through Lilly directly.

Smart Questions to Ask Your Doctor

Walking into the appointment prepared makes the conversation more productive. Consider asking your doctor these questions:

• "Based on my health history, am I a better candidate for an oral or injectable GLP-1?" — Your doctor can weigh factors like your diabetes status, weight loss goals, and medication preferences.
• "How does Foundayo's weight loss compare to what I might achieve with an injectable?" — Be realistic about the 12% vs. 15-20% difference and whether it matters for your goals.
• "What labs should we check before starting?" — Baseline metabolic panel, thyroid function, and lipids are standard before any GLP-1 initiation.
• "If I'm currently on an injectable GLP-1, what would a transition look like?" — There's now clinical data supporting this switch, but the protocol should be individualized.
• "What's the titration schedule, and how do we manage side effects during the ramp-up?" — Knowing what to expect in weeks 1-8 reduces the chance of early discontinuation.

The Bottom Line

Foundayo is a genuinely new option in the GLP-1 landscape — not just another injectable reformulation. Its no-restriction oral dosing, solid clinical data, and unique mechanism make it worth discussing with your prescriber, especially if needles or fasting requirements have been barriers to treatment.

That said, it's not a replacement for the higher-efficacy injectables for everyone. The right medication depends on your individual health profile, weight loss goals, insurance coverage, and personal preferences. An informed conversation with your doctor is the best way to figure out where Foundayo fits — or doesn't — in your treatment plan.